Pfizer: promising trial for Ibrance in breast cancer

(CercleFinance.com) - Pfizer announces that a Phase 3 trial demonstrated that the addition of Ibrance (palbociclib) to standard maintenance therapy 'significantly' improved progression-free survival (PFS) in patients with HR+/HER2+ metastatic breast cancer (MBC).


Median PFS was 44.3 months with Ibrance, versus 29.1 months with standard therapy alone, a gain of over 15 months.

Overall survival, a secondary endpoint, was not yet mature.

This study confirms the potential of Ibrance as maintenance therapy to slow disease progression.

Results will be shared with regulatory authorities.


Copyright (c) 2024 CercleFinance.com. All rights reserved.